The review of serotonin-selective reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medicines looked at the potential risk of suicidal behavior in children and adolescents treated with these
The Ottawa Statement was published in the British Medical Journal (BMJ). It outlines three key principles for registration to help ensure clinicians, researchers, patients and the public have
The nanoparticles can reveal tiny cancerous tumors that are invisible by ordinary means of detection, according to the researchers at Washington University School of Medicine in St Louis.
The data were presented at the 75th European Atherosclerosis Society (EAS) Congress in Prague, the Czech Republic. The first presentation included new data from four studies (MERCURY II,
The European Commission will have 90 working days, subject to possible extensions, to issue an opinion on the matter. Johnson & Johnson and Guidant Corporation said that they
The two companies have signed a definitive agreement under which Shire has agreed to acquire TKT. Shire will pay $37 in cash for each share of TKT common
Temodal (temozolomide) is currently approved in the EU for the treatment of patients with malignant glioma such as glioblastoma multiforme (GBM), or anaplastic astrocytoma, showing recurrence or progression
Kali has been awarded 180 days of marketing exclusivity for being the first to file an abbreviated new drug application (ANDA) containing a paragraph IV certification for the
The collaboration will use Telik’s proprietary drug discovery technology, Trap (target-related affinity profiling), which enables the discovery of small molecule product candidates by taking advantage of the fundamental
Advancis’ pediatric pivotal program is designed as a 500-patient, investigator-blind, non-inferiority phase III trial for a ‘sprinkle’ formulation of amoxicillin Pulsys for the treatment of pediatric patients with
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.